THETFORD MINES, QUEBEC–(Marketwired – Aug. 26, 2016) – AlliancePharma Inc. (TSX VENTURE:APA) (“AlliancePharma” or the “Corporation“) is pleased to announce the appointment of Dr. Sheldon Elman as a member of the board of directors of the Corporation. Dr. Elman is the Founder and Chairman of Medisys Health Group Inc., Canada’s leading provider of comprehensive, preventive and corporate health solutions, as well as a Founding Partner of Persistence Capital Partners, a private equity fund specializing in health care. “I am very excited that Dr. Elman has joined the board of directors of AlliancePharma,” said Marc Lemieux, President and CEO of AlliancePharma. “Dr. Elman brings a great deal of board experience as well as extensive knowledge in the healthcare industry.”
Additionally, the Corporation wishes to announce the resignation of Dr. Sami B. Chaouch from the board of directors. The Corporation wishes to thank Dr. Chaouch for his services and contributions to the Corporation and wishes him well in his future endeavors.
About AlliancePharma
AlliancePharma is a leading solution and service provider to the pharmaceutical market. Today it is a respected name for quality and expertise among pharmacists. Its management team is guided by a vision of continuing to lead the way in Quebec while extending operations across Canada and internationally. Additional information on the Corporation is available at www.alliancepharmainc.ca and on SEDAR at www.sedar.com.
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
This press release from AlliancePharma contains forward-looking statements. Forward-looking statements are typically identified by the words assumption, goal, guidance, objective, outlook, strategy, target, and other similar expressions, or future or conditional verbs such as aim, anticipate, believe, predict, could, expect, intend, may, plan, seek, should, strive, and will. By their nature, forward-looking statements require us to make estimates and assumptions and express opinions based on current conditions and anticipated developments, as well as other factors that Management may deem appropriate under the circumstances. There is inherent uncertainty and significant risk in these estimates, assumptions, and opinions, particularly of a commercial, economic, and competitive nature, and they are therefore subject to change. AlliancePharma cannot guarantee that these estimates, assumptions, and opinions will prove to be accurate.
Readers are cautioned not to accord undue credibility to such forward-looking statements, which are based solely on AlliancePharma’s expectations as of the date of this press release. AlliancePharma declines all responsibility to update or revise its forward-looking statements, whether to account for new information or future events or circumstances, unless legally obligated to do so.
This press release does not constitute an offer to sell or the solicitation of an offer to buy securities in the United States, or in any jurisdiction in which such offer, solicitation, or sale would be unlawful. The securities described in this press release have not been and will not be registered under the United States Securities Act of 1933, as amended, nor under any State securities law, and may not be offered for sale or sold in the United States, unless registered in compliance with these laws or dispensed from such registration.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this News Release.
TACT Intelligence – Conseil
514-349-7778
mparent@tactconseil.ca